弥漫大b站细胞淋巴瘤治疗新进展.pptVIP

概述 流行病学 基于分子生物学改变的预后评价 治疗进展 初治的DLBCL 难治复发的DLBCL 新药临床试验 基于基因表达的风险评分-- 预测DLBCL临床结果 CHOP R-CHOP Winter JN, et al. ASH 2011. Abstract 87. Probability 1.0 0.8 0.6 0.4 0.2 0 12 0 2 4 6 8 10 Yrs FFS P = .003 Median ≥ Median 1.0 0.8 0.6 0.4 0.2 0 12 0 2 4 6 8 10 Yrs OS P = .001 Median ≥ Median 1.0 0.8 0.6 0.4 0.2 0 12 0 2 4 6 8 10 Yrs FFS P = .001 1.0 0.8 0.6 0.4 0.2 0 12 0 2 4 6 8 10 Yrs OS P = .0015 基于基因表达的风险评分-- 预测DLBCL临床结果 High- vs low-gene risk scores significantly predicted OS CHOP (median follow-up: 7.6 yrs; P .0001